Cowen & Co. Keeps Their Buy Rating on Esperion (ESPR)


In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Esperion (ESPR), with a price target of $85. The company’s shares opened today at $49.50.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.5% and a 42.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $75.56, implying a 52.6% upside from current levels. In a report issued on May 6, Jefferies also maintained a Buy rating on the stock with a $85 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $60.99 and a one-year low of $35.80. Currently, Esperion has an average volume of 585.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts